Posted on 7/22/20
NovoCure: A Disrupter In Oncology
SummaryThis disruptive medtech player in oncology is up >7x since I started covering it on Seeking Alpha in 2016.The recent pullback in the stock has offered . . .
Posted on 11/25/19
Allena Pharmaceuticals: Rating This Stock A Buy
SummaryReloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.Reloxaliase has a . . .
Posted on 11/22/19
Allena Pharmaceuticals: Rating This Stock A Buy
SummaryReloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.Reloxaliase has a . . .
Posted on 7/17/19
Dova Pharmaceuticals: Analysis Of Doptelet's Potential In Various Thrombocytopenias
SummaryThe company’s lead product is Doptelet (avatrombopag), an oral, thrombopoietin receptor agonist, which received FDA approval for treating refractory chronic idiopathic thrombocytopenia in adults.Doptelet is also . . .
Philadelphia
